Larkin J, Chiarion-Sileni V, Gonzalez R, et al. - Researchers reported 5-year outcomes with nivolumab and ipilimumab (both combined and alone) in a trial involving patients with formerly untreated advanced melanoma. In the nivolumab-plus-ipilimumab group and in the nivolumab group, overall survival at 5 years was 52% and 44%, respectively, in comparison with 26% in the ipilimumab group. During or following treatment with nivolumab plus ipilimumab or with nivolumab alone, no sustained drop of health-related quality of life was noted. No new late toxic impacts were seen. With no evident loss of quality of life in the individuals who received regimens containing nivolumab, at 5 years, sustained long-term overall survival was noted in a greater number of patients who received nivolumab plus ipilimumab or nivolumab alone in comparison with those who received ipilimumab alone.